Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (37)
Hui Lyu, Fei Shen, Sanbao Ruan, Congcong Tan, Jundong Zhou, Ann D. Thor & Bolin Liu. (2023) HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel. Cancer Cell International 23:1.
Crossref
Crossref
Hui Lyu, Defu Hou, Hao Liu, Sanbao Ruan, Congcong Tan, Jiande Wu, Chindo Hicks & Bolin Liu. (2023) HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells. npj Precision Oncology 7:1.
Crossref
Crossref
Silvia Mara Baez Rodriguez, Amira Kamel, Gheorghe Vasile Ciubotaru, Gelu Onose, Ani-Simona Sevastre, Veronica Sfredel, Suzana Danoiu, Anica Dricu & Ligia Gabriela Tataranu. (2023) An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. International Journal of Molecular Sciences 24:13, pages 11110.
Crossref
Crossref
Xiao Zhao & Des R. Richardson. (2023) The role of the NDRG1 in the pathogenesis and treatment of breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:3, pages 188871.
Crossref
Crossref
Yingying Song, Meena Kishore Sakharkar & Jian Yang. (2023) Probing the mechanism of action (MOA) of Solanum nigrum Linn against breast cancer using network pharmacology and molecular docking. SN Applied Sciences 5:5.
Crossref
Crossref
Elena Levantini, Giorgia Maroni, Marzia Del Re & Daniel G. Tenen. (2022) EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Biology 85, pages 253-275.
Crossref
Crossref
Carlos Garcia-Padilla, Estefanía Lozano-Velasco, María del Mar Muñoz-Gallardo, Juan Manuel Castillo-Casas, Sheila Caño-Carrillo, Francisco José Martínez-Amaro, Virginio García-López, Amelia Aránega, Diego Franco, Virginio García-Martínez & Carmen López-Sánchez. (2022) LncRNA H19 Impairs Chemo and Radiotherapy in Tumorigenesis. International Journal of Molecular Sciences 23:15, pages 8309.
Crossref
Crossref
Fengping Huang. (2022) Research Progress of Nanomaterial Mechanics for Targeted Treatment of Muscle Strains in Sports Rehabilitation Training. Applied Bionics and Biomechanics 2022, pages 1-9.
Crossref
Crossref
Zhenchao Wang, Guiping Ouyang, Sili Fan, Yihong Fu, Siyu Tang, Danping Chen, Zhurui Li, Chengpeng Li & Lihui Shao. (2022) Design, Synthesis and Biological Evaluation of Novel Indole-Containing Sorafenib Derivatives. HETEROCYCLES 104:4, pages 667.
Crossref
Crossref
Andrea Botticelli, Giulia Pomati & Paolo Marchetti. 2022. Nuclear Medicine and Molecular Imaging. Nuclear Medicine and Molecular Imaging
288
296
.
Zainab Al-Taie, Mark Hannink, Jonathan Mitchem, Christos Papageorgiou & Chi-Ren Shyu. (2021) Drug Repositioning and Subgroup Discovery for Precision Medicine Implementation in Triple Negative Breast Cancer. Cancers 13:24, pages 6278.
Crossref
Crossref
Sudpreeda Chainitikun, Sadia Saleem, Bora Lim, Vicente Valero & Naoto T. Ueno. (2021) Update on systemic treatment for newly diagnosed inflammatory breast cancer. Journal of Advanced Research 29, pages 1-12.
Crossref
Crossref
Jingrui Liu, Hong Zhang, Xiaoxue Zhu, Hong Chen, Xiaojiao Li & Yanhua Ding. (2021) Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Frontiers in Pharmacology 12.
Crossref
Crossref
Zhili Wen, Yuliang Feng, Youwen Hu, Lingyan Lian, Hongyan Huang, Li Guo, Shanwen Chen, Qian Yang, Moran Zhang, Lijun Wan, Kedong Xu, Degejirifu & Xiaohua Yan. (2021) Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer. Aging 13:2, pages 1872-1882.
Crossref
Crossref
Elias da Silva Santos, Karina Alexandre Barros Nogueira, Luiziana Cavalcante Costa Fernandes, Jéssica Roberta Pereira Martins, Alice Vitoria Frota Reis, José de Brito Vieira Neto, Ivanildo José da Silva Júnior, Claudia Pessoa, Raquel Petrilli & Josimar O. Eloy. (2021) EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. International Journal of Pharmaceutics 592, pages 120082.
Crossref
Crossref
Hongyan Jin. 2021. Aptamers for Medical Applications. Aptamers for Medical Applications
405
462
.
Miguel Angel Galván Morales, Raúl Barrera Rodríguez, Julio Raúl Santiago Cruz & Luis M. Teran. (2020) Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. Molecules 25:23, pages 5686.
Crossref
Crossref
Melyssa S. Roberts, Lindsey J. Anstine, Viviane S. Finke, Benjamin L. Bryson, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Parth R. Majmudar & Ruth A. Keri. (2020) KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene. Breast Cancer Research 22:1.
Crossref
Crossref
Xiaoping Wang, Takashi Semba, Lan Thi Hanh Phi, Sudpreeda Chainitikun, Toshiaki Iwase, Bora Lim & Naoto T. Ueno. (2020) Targeting Signaling Pathways in Inflammatory Breast Cancer. Cancers 12:9, pages 2479.
Crossref
Crossref
Yolanda Jerez, Blanca Herrero, Marta Arregui, Blanca Morón, Miguel Martín & Isabel Echavarría. (2020) Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer. Future Oncology 16:17, pages 1165-1177.
Crossref
Crossref
Wei Jing, Jie-Tao Ma & Cheng-Bo Han. (2020) Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report. Frontiers in Oncology 10.
Crossref
Crossref
Kenny Chitcholtan, Dianne Harker, Bryony Simcock & Peter Sykes. (2020) Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors. Applied Sciences 10:7, pages 2343.
Crossref
Crossref
Renaud Sabatier, Marc Lopez, Arnaud Guille, Emilien Billon, Nadine Carbuccia, Séverine Garnier, José Adelaide, Jean-Marc Extra, Maria-Antonietta Cappiello, Emmanuelle Charafe-Jauffret, Jihane Pakradouni, Patrice Viens, Anthony Gonçalves, Max Chaffanet, Daniel Birnbaum & François Bertucci. (2019)
High Response to Cetuximab in a Patient With
EGFR
-Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer
. JCO Precision Oncology:3, pages 1-8.
Crossref
Crossref
Yohei Funakoshi, Ying Wang, Takashi Semba, Hiroko Masuda, David Hout, Naoto T. Ueno & Xiaoping Wang. (2019) Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. PLOS ONE 14:9, pages e0222336.
Crossref
Crossref
Rintu Thomas & Zhang Weihua. (2019) Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Frontiers in Oncology 9.
Crossref
Crossref
Xiaoli Dai, Qing Zhang, Huili Zhang & Hongtao Xu. (2019) Identifying peptides that specifically bind to MDA-MB-468 breast cancer cells*. Oncology and Translational Medicine 5:3, pages 119-122.
Crossref
Crossref
Rintu Thomas, Shivangi Srivastava, Rajasekhara Reddy Katreddy, Jason Sobieski & Zhang Weihua. (2019) Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors. International Journal of Molecular Sciences 20:10, pages 2515.
Crossref
Crossref
Bo Peng, Rong He, Qihua Xu, Yifei Yang, Qin Hu, Hongping Hou, Xinmin Liu & Jianrong Li. (2019) Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway. Pharmacological Research 142, pages 1-13.
Crossref
Crossref
Yi Zhu, ZhiHeng Chen, HongGang Jiang & BoHao Lu. (2019) The genetic association between EGF A61G polymorphism (rs4444903) and risk of colorectal cancer. Medicine 98:2, pages e14007.
Crossref
Crossref
Ji Hye Im, Keon Wook Kang, Sun Young Kim, Yoon Gyoon Kim, Yong Jin An, Sunghyouk Park, Byung Hwa Jeong, Song-Yi Choi, Jin-Sun Lee & Keon Wook Kang. (2018) GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
Jia Huafeng, Zhang Deqing, Ding Yong, Zhang Yulian & Hu Ailing. (2018) A cross-talk between integrin β4 and epidermal growth factor receptor induces gefitinib chemoresistance to gastric cancer. Cancer Cell International 18:1.
Crossref
Crossref
Chaido Sirinian, Anastasios D. Papanastasiou, Michail Schizas, Magda Spella, Georgios T. Stathopoulos, Maria Repanti, Ioannis K. Zarkadis, Tari A. King & Haralabos P. Kalofonos. (2018) RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling. Oncogene 37:37, pages 5101-5114.
Crossref
Crossref
Naoko Matsuda, Xiaoping Wang, Bora Lim, Savitri Krishnamurthy, Ricardo H. Alvarez, Jie S. Willey, Charla A. Parker, Juhee Song, Yu Shen, Jianhua Hu, Wenhui Wu, Nan Li, Gildy V. Babiera, James L. Murray, Banu K. Arun, Abenaa M. Brewster, James M. Reuben, Michael C. Stauder, Chad M. Barnett, Wendy A. Woodward, H. T. Carisa Le-Petross, Anthony Lucci, Sarah M. DeSnyder, Debu Tripathy, Vicente Valero & Naoto T. Ueno. (2018) Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncology 4:9, pages 1207.
Crossref
Crossref
Bin Xu, Yuan-Jun Zhu, Cheng-Han Wang, Chong Qiu, Jing Sun, Yi Yan, Xin Chen, Jian-Cheng Wang & Qiang Zhang. (2018)
Improved Cell Transfection of siRNA by pH-Responsive Nanomicelles Self-Assembled with mPEG-
b
-PHis-
b
-PEI Copolymers
. ACS Applied Materials & Interfaces 10:26, pages 21847-21860.
Crossref
Crossref
Soon Young Shin, Da Hyun Lee, Jishin Lee, Chan Choi, Ji-Young Kim, Jeong-Seok Nam, Yoongho Lim & Young Han Lee. (2017) C-C motif chemokine receptor 1 (CCR1) is a target of the EGF-AKT-mTOR-STAT3 signaling axis in breast cancer cells. Oncotarget 8:55, pages 94591-94605.
Crossref
Crossref
Vijaya Lakshmi Malisetty, Vasudevarao Penugurti, Prashanth Panta, Suresh Kumar Chitta & Bramanandam Manavathi. (2017) MTA1 expression in human cancers – Clinical and pharmacological significance. Biomedicine & Pharmacotherapy 95, pages 956-964.
Crossref
Crossref
Xiaoping Wang, Monica E. Reyes, Dongwei Zhang, Yohei Funakoshi, Adriana P. Trape, Yun Gong, Takahiro Kogawa, Bedrich L. Eckhardt, Hiroko Masuda, David A. PirmanJrJr, Peiying Yang, James M. Reuben, Wendy A. Woodward, Chandra Bartholomeusz, Gabriel N. Hortobagyi, Debu Tripathy & Naoto T. Ueno. (2017) EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget 8:40, pages 67904-67917.
Crossref
Crossref